Libra Therapeutics Advances LBR-2950 Program securing a $5 Million MJFF grant.

San Diego (CA, USA) – Libra Therapeutics Inc., a Golgi Neuroscience’s Portfolio company developing novel therapeutics to restore cellular balance and attenuate neurodegeneration, has secured a $5 Million grant to advance the LBR-2950 program from the The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Libra’s commitment to fight neurodegenerative diseases continues to drive groundbreaking progress, and MJFF ongoing support fuels their shared mission to transform the lives of those affected by Parkinson’s. condition.

For more details, please go to Libra Therapeutics Website or the Golgi Neuroscience’s Linkedin Page